Kezar Life Sciences
KZR

$0.5700

2.16%

Market Cap: $41.6M

About: Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.

Employees: 58

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

6% less funds holding

Funds holding: 85 [Q1] → 80 (-5) [Q2]

9.16% less ownership

Funds ownership: 63.23% [Q1] → 54.07% (-9.16%) [Q2]

19% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 27

35% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 26

42% less capital invested

Capital invested by funds: $40.5M [Q1] → $23.6M (-$16.9M) [Q2]

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$7

1,128%

upside

Avg. target

$7

1,128%

upside

High target

$7

1,128%

upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Raghuram Selvaraju 44% 1-year accuracy 108 / 246 met price target	1,128%upside $7	Buy Reiterated	14 Aug 2024
HC Wainwright & Co. Raghuram Selvaraju 44% 1-year accuracy 108 / 246 met price target	1,128%upside $7	Buy Maintained	22 Jul 2024

See Analyst Rankings

Financial journalist opinion

Kezar Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that Chris Kirk, Co-founder and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference on Wednesday, September, 11, 2024 at 12:00 pm ET in New York, NY. A webcast of the presentation will be ava.

Kezar Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Kezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today reported financial results for the second quarter ended June 30, 2024, and provided a business update. “We are thrilled to announce completion of enrollment to our PORTOLA trial and look forward to sharing topline results earlier than expected in the first half.

Kezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update

Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that the Compensation Committee of the company's Board of Directors granted one employee a nonqualified stock option to purchase 72,000 shares of its common stock with an exercise price of $0.55 per share, which is equal to the closing price of Kezar'.

Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that the Compensation Committee of the company's Board of Directors granted one employee a nonqualified stock option to purchase 80,000 shares of its common stock with an exercise price of $0.71 per share, which is equal to the closing price of Kezar'.

Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that Chris Kirk, Co-founder and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024, at 12:30 pm ET in New York, NY. A webcast of the panel discussion will be available.

Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference

Kezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today reported financial results for the first quarter ended March 31, 2024 and provided a business update. “We continued to make meaningful progress this past quarter on our mission to develop first-in-class small molecule therapeutics in immunology and oncology. We.

Kezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update

Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that the Compensation Committee of the company's Board of Directors granted two employees nonqualified stock options to purchase 164,000 shares of its common stock with an exercise price of $0.84 per share, which is equal to the closing price of Kezar.

Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Compensation Committee of the company's Board of Directors granted one employee a nonqualified stock option to purchase 12,000 shares of its common stock with an exercise price of $0.93 per share, which is equal to the closing price of Kezar's common stock on April 1,.

Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

From Pennies to Fortunes: 3 Stocks Set to Make Millionaires

A constellation of stocks beckons daring investors from the great expanse of the financial galaxy, where stars glitter with promise and fortunes wait to be discovered. The first stop on the journey is a celestial body whose excellent recovery rates and record-breaking throughput suggest a gold mine of opportunities.

From Pennies to Fortunes: 3 Stocks Set to Make Millionaires

Diamonds in the Dust: 3 Penny Stocks Set to Soar 500% by 2026

Penny stocks provide risk and profit but frequently lie in the shadows in the fast-paced world of investing. Nevertheless, three-penny stocks stand like diamonds in the dust among the chaos and uncertainties.

Diamonds in the Dust: 3 Penny Stocks Set to Soar 500% by 2026

See News Rankings